Sanofi Shares Rise by 1.87% at Close, Reclaiming Its Moving Average
The stock of the French pharmaceutical giant increased by 1.87% this Friday, January 9, closing at 84.44 euros after a session marked by renewed investor interest.
Stock Performance and Technical Analysis
Sanofi's stock rose by 1.87% on Friday to settle at 84.44 euros, up from 82.89 euros the previous day. The traded volumes accounted for 0.16% of the capital, a moderate level but sufficient to materialize the upward movement. The stock is now just below its 50-day moving average at 84.98 euros, a key technical threshold that could be tested in the short term. The RSI stands at 62, in a neutral zone but slightly above the balance of 50, indicating a revival of buying momentum without signaling overbought conditions. Over the past week, the stock has shown a performance of 2.08%, but remains down by 11.74% over the year, reflecting a still challenging sectoral and stock market context for large pharmaceutical capitalizations.
Recent Strategic Announcements
The recent context has been marked by several strategic announcements from the group. On January 5, Sanofi submitted to the FDA a request for an extension of the indication of Tzield to delay type 1 diabetes in children from one year old, with a decision expected in April 2026. At the end of December, the laboratory also finalized the acquisition of Dynavax Technologies for $2.2 billion, notably incorporating the HEPLISAV B vaccine against hepatitis B. On the analysts' side, several banks maintain positive recommendations: Grupo Santander retains an outperformance recommendation with a target price of 106 euros, as does Berenberg with a target of 105 euros, representing a potential upside of between 24 and 26% relative to the current price.
